文献速递核素与放射性配体治疗

血液中PRRT基因组特征预测177Lu-奥曲肽疗效

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-26

本研究在三个独立177Lu-PRRT治疗队列中验证了由血液NET转录本与肿瘤分级整合而成的PRRT预测商(PPQ)对疗效的预测价值,并分别在两个生长抑素类似物治疗队列和一个未治疗队列中检验其特异性与预后价值。结果显示PPQ在验证队列中预测准确率达95%,PPQ+组中位PFS未达到而PPQ-组为10-14个月(HR 18-77,p<0.0001)。

要点

  • PPQ由8个NET血液基因转录本与肿瘤Ki67经逻辑回归整合而成,治疗前给出预测应答者(PPQ+)或预测非应答者(PPQ-)。
  • 验证队列中PPQ预测准确率为95%(Bad Berka PPQ+ 97%、PPQ- 93%;Rotterdam PPQ+ 94%、PPQ- 100%)。
  • 在SSA治疗队列中PPQ准确率为47-50%,作为预后标志准确率为50%,PPQ+与PPQ-组PFS无差异。

核心结论

  • 治疗开始前基于循环NET特异性基因与肿瘤分级得出的PPQ是PRRT疗效的高度特异性预测标志,准确率达95%。

研究设计与样本

  • PPQ的开发与验证在三个独立的177Lu-PRRT治疗队列中进行,特异性在两个独立的生长抑素类似物治疗队列中检验,预后价值在一个未治疗队列中定义。
  • 开发队列来自意大利IRST Meldola,包括肺和胃肠胰(GEP)NET患者n=72,多数为GEP(71%)和低级别(86% G1-G2)。
  • 前瞻性验证队列来自德国Zentralklinik Bad Berka(n=44)和荷兰鹿特丹Erasmus Medical Center(n=42),各队列以高分化、低级别(86-95%)的肺和GEP-NET为主。
  • 非PRRT对照队列包括SSA队列I n=28(100%低级别,100% GEP-NET)、SSA队列II n=51(98%低级别,76% GEP-NET)和未治疗队列n=44(64%低级别,91% GEP-NET)。
  • 基线评估包括临床信息(疾病状态、分级、SSR)和生物标志物(CgA),治疗前测量8个NET血液基因转录本并与肿瘤Ki67用逻辑回归模型整合。

主要发现

  • 开发队列中56%对PRRT应答,PPQ预测了100%的应答者和84%的非应答者(准确率93%)。
  • 两个验证队列中应答率为64-79%,PPQ准确率为95%(Bad Berka:PPQ+ 97%、PPQ- 93%;Rotterdam:PPQ+ 94%、PPQ- 100%)。
  • 总体中位PFS在PPQ+组未达到,PPQ-组为10-14个月(HR 18-77,p<0.0001)。
  • 在对照队列中,PPQ对SSA治疗的预测准确率为47-50%,作为预后标志准确率为50%,PPQ+组PFS 10-12个月 vs PPQ-组9-15个月,未见差异。

关键数值与推荐

  • PPQ由8个NET血液基因转录本(生长因子信号与代谢)与肿瘤Ki67经逻辑回归模型整合,输出二分类:预测应答者(PPQ+)或预测非应答者(PPQ-)。
  • 疗效评估采用RECIST标准,应答者包括疾病稳定、部分缓解和完全缓解,非应答者对应疾病进展。
  • 样本测量与分析对研究结局设盲。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy. Intensity of uptake at imaging is considered related to efficacy but has low sensitivity. A pretreatment strategy to determine individual PRRT response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ) which stratifies PRRT "responders" from "non-responders". This study clinically validates the utility of the PPQ in NETs. METHODS: The development and validation of the PPQ was undertaken in three independent 177Lu-PRRT treated cohorts. Specificity was tested in two separate somatostatin analog-treated cohorts. Prognostic value of the marker was defined in a cohort of untreated patients. The developmental cohort included lung and gastroenteropancreatic [GEP] NETs (n = 72) from IRST Meldola, Italy. The majority were GEP (71%) and low grade (86% G1-G2). Prospective validation cohorts were from Zentralklinik Bad Berka, Germany (n = 44), and Erasmus Medical Center, Rotterdam, Netherlands (n = 42). Each cohort included predominantly well differentiated, low grade (86-95%) lung and GEP-NETs. The non-PRRT comparator cohorts included SSA cohort I, n = 28 (100% low grade, 100% GEP-NET); SSA cohort II, n = 51 (98% low grade; 76% GEP-NET); and an untreated cohort, n = 44 (64% low grade; 91% GEP-NET). Baseline evaluations included clinical information (disease status, grade, SSR) and biomarker (CgA). NET blood gene transcripts (n = 8: growth factor signaling and metabolism) were measured pre-therapy and integrated with tumor Ki67 using a logistic regression model. This provided a binary output: "predicted responder" (PPQ+); "predicted non-responder" (PPQ-). Treatment response was evaluated using RECIST criteria [Responder (stable, partial and complete response) vs Non-Responder)]. Sample measurement and analyses were blinded to study outcome. Statistical evaluation included Kaplan-Meier survival and standard test evaluation analyses. RESULTS: In the developmental cohort, 56% responded to PRRT. The PPQ predicted 100% of responders and 84% of non-responders (accuracy: 93%). In the two validation cohorts (response: 64-79%), the PPQ was 95% accurate (Bad Berka: PPQ + =97%, PPQ- = 93%; Rotterdam: PPQ + =94%, PPQ- = 100%). Overall, the median PFS was not reached in PPQ+ vs PPQ- (10-14 months; HR: 18-77, p < 0.0001). In the comparator cohorts, the predictor (PPQ) was 47-50% accurate for SSA-treatment and 50% as a prognostic. No differences in PFS were respectively noted (PPQ+: 10-12 months vs. PPQ-: 9-15 months). CONCLUSION: The PPQ derived from circulating NET specific genes and tumor grade prior to the initiation of therapy is a highly specific predictor of the efficacy of PRRT with an accuracy of 95%.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bodei L, Kidd MS, Singh A, et al. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018. PMID: 29484451. doi:10.1007/s00259-018-3967-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。